The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...
Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...
1d
ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.
Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.
A recent study found that participants who practice mindfulness reported significantly less severe symptoms of anxiety, ...
The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...
Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...
Dr Sundeep Salvi: Shardul Nautiyal, Mumbai Tuesday, March 4, 2025, 08:00 Hrs [IST] Chronic obstructive pulmonary disease (C ...
chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant. It ...
Recent research published in The Lancet Respiratory Medicine confirms that emphysema was detected in 24% to 31% of patients undergoing lung cancer screening. This means that for millions of Americans, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback